About Graviton BioScience
Graviton BioScience is a private company based in New York, New York, incorporated in 2020 in Delaware. It has reported $93,319,490 raised in four offerings on Form D since February 2021. Its chief executive is Samuel Waksal.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Jan 31, 2024 | Feb 14, 2024 | $24,999,996fully sold | 1 | $24.9M | EquityRule 506(b) | Form D ↗ |
| Dec 20, 2022 | Dec 4, 2023 | $39,819,496of $50.0M target | 11 | $3.6M | EquityRule 506(b) | Form D ↗ |
| Nov 22, 2023 | Dec 4, 2023 | $24,999,998fully sold | 1 | $24.9M | EquityRule 506(b) | Form D ↗ |
| Feb 4, 2021 | Feb 19, 2021 | $3,500,000of $30.0M target | 3 | $1.1M | EquityRule 506(b) | Form D ↗ |
| Total, four offerings | $93,319,490 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Graviton BioScience's Form D filed Feb 14, 2024.
SW
Samuel Waksal
Chief Executive Officer and director
BC
Bihua Chen
Director
JL
Jeremy Levin
Director
DM
David MacMillan
Director
JB
James Boylan
Director
SP
Stelios Papadopoulos
Director
RN
Ran Nussbaum
Director
Earlier filings also listed Steven Gordon (secretary and director, last listed Feb 2021), Richard Giroux (director, last listed Feb 2021) and Philip Barach (director, last listed Feb 2021).